CJC-1295

Growth hormone-releasing hormone analog · Also known as Modified GRF 1-29, Mod GRF, CJC-1295 without DAC

What is CJC-1295?

The short-acting form of CJC-1295, also known as Modified GRF 1-29. It has a half-life of about 30 minutes, producing sharp, natural-pattern growth hormone pulses when injected. Most commonly paired with ipamorelin.

CJC-1295 without DAC (Modified GRF 1-29) is a synthetic 29-amino-acid GHRH analog with four amino acid substitutions that protect it from enzymatic degradation. Unlike the DAC version, it clears quickly and produces acute GH spikes that closely mimic the body's natural pulsatile release pattern. This short half-life is actually an advantage for people who want to preserve normal GH physiology while boosting peak levels.

Key takeaway: CJC-1295 without DAC produces sharp, natural-pattern GH pulses and is most commonly stacked with ipamorelin for synergistic growth hormone release.

Benefits & evidence

Sustained GH and IGF-1 elevation Moderate confidence
Muscle growth support Preliminary confidence
Fat metabolism Preliminary confidence
Improved sleep quality Preliminary confidence
Recovery and repair Preliminary confidence

How it works

CJC-1295 (no DAC) binds to GHRH receptors on pituitary somatotroph cells, stimulating them to synthesize and secrete growth hormone. Because it clears from the bloodstream in roughly 30 minutes, the resulting GH spike is sharp and brief, closely mimicking the body's natural pulsatile release.

This is a key difference from the DAC version, which binds to albumin and stays active for days, creating a sustained but non-pulsatile GH elevation. Many researchers prefer the no-DAC form precisely because it preserves the natural pulse pattern and feedback loops. It is almost always paired with a secretagogue like ipamorelin, which amplifies each GH pulse.

Dosing information

Typical dosing protocol
Starting dose

100 mcg (no DAC) 1-2x daily

Weeks 1-4
Maintenance dose

100-200 mcg (no DAC) before bed, or 1-2 mg (DAC) 1-2x weekly

8-12 weeks

The no-DAC form is typically combined with ipamorelin and injected on an empty stomach. The DAC form requires less frequent dosing. Consult your healthcare provider for protocol guidance.

Side effects

Most side effects tend to improve as your body adjusts.

Injection site reaction Common
Flushing Common
Headache Uncommon
Water retention Uncommon
Dizziness Rare

Research (13 studies)

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026